Breaking the Transmission of TB: A Roadmap to Bridge the Gaps in Controlling TB in Endemic Settings

  • Pooja Singh
  • Jasmine Samal
  • Sheeba Zarin
  • Ravikrishnan Elangovan
  • Seyed E. Hasnain
  • Nasreen Z. EhteshamEmail author


Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), remains an enormous health burden with nearly 2 billion people worldwide being affected by it, though only 10% progress to active disease. Currently around 58% of people infected with M.tb are being diagnosed and treated. The lack of a standard research setting and limited resource in terms of early diagnosis of TB lead to high incidence of transmission of TB infection in high-TB-burden countries. Therefore, early diagnosis of TB and an effective vaccination can primarily break the cycle of transmission of TB. Recommended diagnostic tests, currently available, have several limitations, making them unsuitable for resource-limited settings and remote areas. The healthcare settings are the highest risk zones for transmission of drug-resistant M.tb strains. Multidrug-resistant (MDR) TB is resilient to diagnosis and pose major complications to patient’s health during treatment. In order to limit the spread of MDR TB, we need to implement better diagnostic tools and health measures which may eventually interrupt transmission of M.tb from TB patients to uninfected individuals. Complete and correct execution of regime of anti-TB therapies at both the individual and community level could help in minimizing the transmission of TB. This chapter gives an insight on strategies that aid in interruption of transmission of TB, especially in high-TB-burden areas across the globe.


Tuberculosis Transmission Mycobacterium tuberculosis Diagnosis Vaccine 



Bacillus Calmette-Guerin


Deoxyribonucleic acid


Government of India


Line probe assays


Loop-mediated isothermal amplification


Mycobacterium tuberculosis


Multidrug resistant


National Strategic Plan


Nonhuman primate


Nucleic acid amplification tests


Revised National Tuberculosis Control Program




Time to detection




World Health Organization


Extensively drug resistant


  1. Ailinger RL, Dear MR (1997) Latino immigrants’ explanatory models of tuberculosis infection. Qual Health Res 7:521–531CrossRefGoogle Scholar
  2. Andersen P, Doherty TM (2005) The success and failure of BCG – implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3:656–662CrossRefGoogle Scholar
  3. Ayisi JG, van’t Hoog AH, Agaya JA, Mchembere W, Nyamthimba PO, Muhenje O, Marston BJ (2011) Care seeking and attitudes towards treatment compliance by newly enrolled tuberculosis patients in the district treatment programme in rural western Kenya: a qualitative study. BMC Public Health 11:515CrossRefGoogle Scholar
  4. Calmette A (1927) La Vaccination préventive contre la tuberculose par le “BCG”. Masson et Cie, ParisGoogle Scholar
  5. Denkinger CM, Nicolau I, Ramsay A, Chedore P, Pai M (2013) Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur Respir J 42:544–547CrossRefGoogle Scholar
  6. Dockrell HM (2016) Towards new TB vaccines: What are the challenges? Pathog Dis 74:ftw016CrossRefGoogle Scholar
  7. Douglas KS (2010) Decrease in the effectiveness of Bacille Calmette-Guérin Vaccine against pulmonary tuberculosis: a consequence of increased immune suppression by microbial antioxidants, not overattenuation. Clin Infect Dis 51:177–184CrossRefGoogle Scholar
  8. Fine PEM (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339–1345CrossRefGoogle Scholar
  9. Lambert ML, Van der Stuyft P (2005) Editorial: delays to tuberculosis treatment: shall we continue to blame the victim? Trop Med Int Heal 10:945–946CrossRefGoogle Scholar
  10. Liefooghe R, Baliddawa JB, Kipruto EM, Vermeire C, De Munynck AO (1997) From their own perspective. A Kenyan community’s perception of tuberculosisCrossRefGoogle Scholar
  11. Lin H-H, Ezzati M, Murray M (2007) Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med 4:e20CrossRefGoogle Scholar
  12. Nardell EA (2004) Catching droplet nuclei. Am J Respir Crit Care Med 169:553–554. Scholar
  13. Nathavitharana RR, Hillemann D, Schumacher SG, Schlueter B, Ismail N, Omar SV, Sikhondze W, Havumaki J, Valli E, Boehme C, Denkinger CM (2016) Multicenter noninferiority evaluation of hain genotype MTBDRplus version 2 and Nipro NTM+MDRTB Line probe assays for detection of rifampin and isoniazid resistance. J Clin Microbiol 54:1624–1630CrossRefGoogle Scholar
  14. Nieuwenhuizen NE, Kulkarni PS, Shaligram U, Cotton MF, Rentsch CA, Eisele B, Grode L, Kaufmann SHE (2017) The recombinant Bacille Calmette-Guérin Vaccine VPM1002: ready for clinical efficacy testing. Front Immunol 8:1147CrossRefGoogle Scholar
  15. O’Shea MK, Koh GCKW, Munang M, Smith G, Banerjee A, Dedicoat M (2014) Time-to-detection in culture predicts risk of mycobacterium tuberculosis transmission: a cohort study. Clin Infect Dis 59:177–185CrossRefGoogle Scholar
  16. RNTCP (2017) World TB day slogansGoogle Scholar
  17. Rodrigues LC, Diwan VK, Wheeler JG (1993) Protective effect of BCG against Tuberculous meningitis and Miliary Tuberculosis: a meta-analysis. Int J Epidemiol 22:1154–1158CrossRefGoogle Scholar
  18. Sharma N, Malhotra R, Taneja DK, Saha R, Ingle GK (2007) Awareness and perception about tuberculosis in the general population of Delhi. Asia Pacific J Public Health 19:10–15CrossRefGoogle Scholar
  19. Sharma KS, Katoch K, Sarin R, Balambal R, Kumar Jain N, Patel N, Murthy KJR, Singla N, Saha PK, Khanna A, Singh U, Kumar S, Sengupta A, Banavaliker JN, Chauhan DS, Sachan S, Wasim M, Tripathi S, Dutt N, Jain N, Joshi N, Penmesta SRR, Gaddam S, Gupta S, Khamar B, Dey B, Mitra DK, Arora SK, Bhaskar S, Rani R (2017) Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial. Sci Rep 7:3354CrossRefGoogle Scholar
  20. Springett VH, Sutherland I (1994) A re-examination of the variations in the efficacy of BCG vaccination against tuberculosis in clinical trials. Tuber Lung Dis 75:227–233CrossRefGoogle Scholar
  21. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M (2006) Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 6(9):570–581CrossRefGoogle Scholar
  22. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, MVA85A 020 Trial Study Team the M 020 TS (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381:1021–1028CrossRefGoogle Scholar
  23. Tollefson D, Ngari F, Mwakala M, Gethi D, Kipruto H, Cain K, Bloss E (2016) Under-reporting of sputum smear-positive tuberculosis cases in Kenya. Int J Tuberc Lung Dis 20:1334–1341CrossRefGoogle Scholar
  24. Trauer JM, Denholm JT, McBryde ES (2014) Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the Asia-pacific. J Theor Biol 358:74–84CrossRefGoogle Scholar
  25. Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, Detjen A, Fujiwara PI, Graham SM, Monedero I, Rusen ID, Rieder HL (2011) Xpert ® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 15:1567–1572CrossRefGoogle Scholar
  26. Trunz B Bourdin, Fine PEM DC (2006) Articles. Lancet 367:1173–1180CrossRefGoogle Scholar
  27. UNITAID (2016) UNITAIDGoogle Scholar
  28. UNITAID (2017) Tuberc diagnostics technol landscapeGoogle Scholar
  29. Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié M-A, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR (2018) Phase 2b controlled trial of M72/AS01E vaccine to prevent Tuberculosis. N Engl J Med 379:1621–1634CrossRefGoogle Scholar
  30. Wandwalo ER, Mørkve O (2000) Delay in tuberculosis case-finding and treatment in Mwanza, Tanzania. Int J Tuberc Lung Dis 4(2):133–138PubMedGoogle Scholar
  31. WHO (2014) TB Global 2014Google Scholar
  32. WHO (2016) World Health Organization GenevaGoogle Scholar
  33. WHO (2017) Global Tuberculosis report 2017-main textGoogle Scholar
  34. WHO (2018) WHO Global Tuberculosis reportGoogle Scholar
  35. Wilson ME, Fineberg HV, Colditz GA (1995) Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. Clin Infect Dis 20:982–991CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Pooja Singh
    • 1
  • Jasmine Samal
    • 2
  • Sheeba Zarin
    • 2
  • Ravikrishnan Elangovan
    • 3
  • Seyed E. Hasnain
    • 1
    • 4
  • Nasreen Z. Ehtesham
    • 2
    Email author
  1. 1.JH Institute of Molecular Medicine, Jamia HamdardNew DelhiIndia
  2. 2.Inflammation Biology and Cell Signaling LaboratoryICMR-National Institute of Pathology, Safdarjung Hospital CampusNew DelhiIndia
  3. 3.Department of Biochemical Engineering and BiotechnologyIndian Institute of Technology-DelhiNew DelhiIndia
  4. 4.Dr Reddy’s Institute of Life SciencesUniversity of Hyderabad CampusHyderabadIndia

Personalised recommendations